Ephrin receptor type-A2 (EphA2) targeting in cancer: a patent review (2018-present).

Despite the availability of a plethora of chemically diverse agents, there are no approved anticancer drugs targeting EphA2 yet. However, these intellectual properties, some of which supported by strong preclinical evidence, keep the hope that, after more than thirty years from its discovery, we will finally see the first EphA2 targeting agent approved in clinical oncology.